Wuhan Vanz Pharmaceutical Co., Ltd.

Wuhan Vanz Pharm Inc.), located in Wuhan, Hubei Province, was established in 2011 (some B2B files are recorded as 2016). It is a API (API), pharmaceutical intermediates, fine chemicals, peptides and food additives that integrate R&D, production and sales. Its products are sold worldwide. The company has a R&D center of about 1000 square meters in Wuhan (including multiple synthesis laboratories, pilot amplification laboratories and analytical laboratories). The manufacturing base is equipped with 100L-5000L reactors, which can provide one-stop services from R&D to commercial production. With long-term cooperation from Shanghai Institute of Organic Chemistry and Wuhan University, it has completed more than 20 APIs and intermediates R&D. Business covers custom synthesis (CDMO/CMC orientation), API contract production, quality control and regulatory consulting. Note: The company uses small molecule APIs/intermediates and custom synthesis as its core business, and peptides is only one of its product categories, not a dedicated peptide API factory.

Wuhan Vanz Pharmaceutical Co., Ltd. is located at Room 414, Longyang Avenue Jingkaiweilaichengzuo, Hanyang District, Wuhan, China.

Main peptides produced: BPC-157, GHK-Cu, Semax, TB-500 (Thymosin Beta-4), DSIP.

Finished peptide dosage forms available.

Website: https://www.vanzpharm.com